We are live on ! Find out more
CM

CM Management Portfolio holdings

AUM $120M
1-Year Est. Return 37.12%
This Fund
S&P 500
This Quarter Est. Return
-5.23%
1 Year Est. Return
+37.12%
3 Year Est. Return
+141.34%
5 Year Est. Return
+139.46%
10 Year Est. Return
–
AUM
$99.5M
AUM Growth
-$12.5M
Cap. Flow
-$3.66M
Cap. Flow %
-3.68%
Top 10 Hldgs %
41.5%
Holding
62
New
5
Increased
25
Reduced
4
Closed
8

Top Buys

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$1.84M
2
IOVA icon
Iovance Biotherapeutics
IOVA
+$1.03M
3
HRI icon
Herc Holdings
HRI
+$852K
4
SWK icon
Stanley Black & Decker
SWK
+$843K
5
WBD icon
Warner Bros
WBD
+$837K

Top Sells

Rank Stock Value
1
RPRX icon
Royalty Pharma
RPRX
+$4.08M
2
CPA icon
Copa Holdings
CPA
+$2.64M
3
B
Barrick Mining
B
+$1.94M
4
CLPT icon
ClearPoint Neuro
CLPT
+$1.79M
5
PAAS icon
Pan American Silver
PAAS
+$1.62M

Sector Composition

Rank Sector Weight
1 Healthcare 36.19%
2 Materials 10.41%
3 Industrials 10.18%
4 Technology 9.3%
5 Financials 9.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALCO icon
1
Alico
ALCO
$298M
$6.71M 6.75%
225,000
– –
TGB
2
Trekor Metals
TGB
$2.57B
$5.49M 5.51%
2,450,000
– –
RLGT icon
3
Radiant Logistics
RLGT
$414M
$4.77M 4.79%
775,000
– –
RIGL icon
4
Rigel Pharmaceuticals
RIGL
$734M
$4.5M 4.52%
250,000
+7,500
+3% +$152K
PLPC icon
5
Preformed Line Products
PLPC
$1.57B
$3.92M 3.94%
28,000
+1,000
+4% +$136K
FOLD
6
DELISTED
Amicus Therapeutics
FOLD
$3.67M 3.69%
450,000
– –
TALO icon
7
Talos Energy
TALO
$2.37B
$3.4M 3.42%
350,000
– –
NMRK icon
8
Newmark Group
NMRK
$2.75B
$3.35M 3.36%
275,000
-25,000
-8% -$334K
BGC icon
9
BGC Group
BGC
$5.36B
$2.75M 2.76%
300,000
+25,000
+9% +$234K
PD icon
10
PagerDuty
PD
$797M
$2.74M 2.75%
150,000
– –
FCX icon
11
Freeport-McMoran
FCX
$84.5B
$2.65M 2.66%
70,000
+20,000
+40% +$765K
INTT icon
12
inTEST
INTT
$170M
$2.62M 2.63%
375,000
+10,000
+3% +$83K
JAZZ icon
13
Jazz Pharmaceuticals
JAZZ
$15.3B
$2.48M 2.49%
20,000
+5,000
+33% +$652K
RBCAA icon
14
Republic Bancorp
RBCAA
$1.78B
$2.23M 2.24%
35,000
– –
OGN icon
15
Organon & Co
OGN
$3.54B
$2.23M 2.24%
150,000
– –
CGAU
16
Centerra Gold
CGAU
$3.02B
$2.22M 2.23%
350,000
– –
ARKO icon
17
ARKO Corp
ARKO
$869M
$2.2M 2.21%
1,050,000
– –
PK icon
18
Park Hotels & Resorts
PK
$2.99B
$2.14M 2.15%
200,000
+50,000
+33% +$633K
THFF icon
19
First Financial Corp
THFF
$908M
$2.08M 2.09%
42,500
– –
CLPT icon
20
ClearPoint Neuro
CLPT
$451M
$2.08M 2.09%
175,000
-115,000
-40% -$1.79M
ARKR icon
21
Ark Restaurants
ARKR
$20.8M
$2.02M 2.03%
200,000
– –
SABR icon
22
Sabre
SABR
$680M
$1.97M 1.98%
700,000
– –
BRKL
23
DELISTED
Brookline Bancorp
BRKL
$1.96M 1.97%
180,000
– –
VTRS icon
24
Viatris
VTRS
$19.8B
$1.96M 1.97%
225,000
+25,000
+13% +$262K
EOLS icon
25
Evolus
EOLS
$365M
$1.8M 1.81%
150,000
– –
1
2 3

Similar funds

AA
Ahara Advisors Jersey City, New Jersey $120M AUM
CC
Commons Capital Needham, Massachusetts $120M AUM 31.45% 1-Year Est. Return
DG
Dala Group Hoffman Estates, Illinois $120M AUM
ACM
AIHC Capital Management Central $120M AUM
WAG
Windsor Advisory Group Columbus, Ohio $120M AUM 4.29% 1-Year Est. Return
YMRC
Yorktown Management & Research Company Forest, Virginia $120M AUM 52.72% 1-Year Est. Return
IW
Integrated Wealthcare Durham, North Carolina $120M AUM
BCWM
Ball & Co Wealth Management Franklin, Tennessee $120M AUM 21.28% 1-Year Est. Return

CM Management's Q1 2025 Portfolio in Review

As of Q1 2025, CM Management held 62 positions worth $99.5M, down 11% from $112M the previous quarter. Its ten largest holdings account for 41% of the portfolio.

CM Management withdrew a net $3.66M in Q1 2025, closing 8 positions and reducing 4 holdings. Its most notable exit was Royalty Pharma, an estimated $4.08M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 36% of assets, down from 40% a quarter earlier, followed by Materials and Industrials.

Against the trend, CM Management opened a new position in Cytokinetics worth $1.61M.

  • CM Management's largest Q1 2025 buy was Cytokinetics: 40,000 shares worth $1.61M.
  • CM Management added most to Iovance Biotherapeutics in Q1 2025, an estimated $1.03M increase.
  • CM Management's biggest Q1 2025 reduction was ClearPoint Neuro, cutting an estimated $1.79M.
  • CM Management fully exited Royalty Pharma in Q1 2025, selling an estimated $4.08M.
  • CM Management's ten largest holdings make up 41% of its $99.5M portfolio in Q1 2025.
  • CM Management opened 5 new positions and closed 8 in Q1 2025.
  • CM Management's portfolio value fell 11% quarter-over-quarter to $99.5M.

Based on CM Management's 13F filing for Q1 2025, filed 9 May 2025.